Skip to Content

High throughput exploration of the design space for antifungal nanocarrier development

School of Pharmacy | PHD

Applications are now CLOSED
Funding
Unfunded
Reference Number
PMY/2251/JT2
Application Deadline
None specified
Start Date
None specified

Overview

Fungal and bacterial infections contribute to over 7 million deaths yearly, affecting over 300 million people globally (GAFFI). Since many antimicrobial drugs are ancient, we are witnessing an unprecedented rise in the emergence of pathogenic resistance to the commonly used antimicrobial drugs (Fisher et al., Nat.Rev.Micro.2022).

Nanomedicine, the use of nanotechnology in developing new medicines, is recognised as one of the Key Enabling Technologies, promising new and innovative solutions to address antimicrobial resistance. Nanocarrier-encapsulated antimicrobial drugs can lower the required dose, enhance the efficacy of the treatment through intracellular delivery, and reduce the chances of antimicrobial drug resistance. Despite these potential benefits, applying a nanoparticle-based drug delivery system requires precise control over the size, drug encapsulation, and a robust production method at commercially practical scales.

Research groups at SoP have been leading the development of a new interdisciplinary research area, the interfaces between design, screening, and scale-up production of antimicrobial nanotherapeutics. The perspective PhD students will work within this dynamic team to develop new high throughput screening (HTS) models for in vitro/ex-vivo selection of antimicrobial nanocarriers.

Due to the highly interdisciplinary nature of this project, candidates with a Master degree are desired. International applicants are welcome, and supports for external funding are available.

The students will work with the PDRAs of the recently established EnLAmB network (MRC project MR/X014010/1), linking with the Centre of Excellence in Infectious Diseases Research at the University of Liverpool (THE LANCET Infectious Diseases, 2021).

Expected Impact Activities:

1. New HTS models for intracellular delivery can provide proof-of-concept for new grant applications, BBRSC or EPSRC.

2. Advances in scalable nano-therapeutical manufacturing can attract new privately funded projects from the industry, CATCH.

3. New antimicrobial nanotherapeutics can lead to new treatments and interventions, iREACH.

Project Summary
Supervisor

Dr Justin Tian

y.tian@qub.ac.uk

Research Profile


Mode of Study

Full-time: 3 years


Apply now Register your interest